Hormonal
Plasma LEAP2 levels increase with higher body mass, obesity, and postprandial states in humans and mice, acting as an endogenous antagonist to acyl-ghrelin to limit food intake and blood glucose elevation.
Your body produces a hormone called LEAP2 that increases when you are overweight or after you eat. This hormone acts as a brake on the 'hunger hormone' (ghrelin) to prevent you from overeating and spiking blood sugar. This is a natural regulatory mechanism. While high LEAP2 is associated with obesity, it also decreases when you lose weight, suggesting your body's hormonal 'brakes' can adjust as your metabolic state changes.
Our results suggest that plasma LEAP2 is regulated by metabolic status: its levels increased with body mass and blood glucose and decreased with fasting, RYGB, and in postprandial states following VSG.
Why this rating
Strong evidence from multiple human cohorts and mouse models, including electrophysiology.
Source
LEAP2 changes with body mass and food intake in humans and mice
Bharath K. Mani et al. · Journal of Clinical Investigation · 2019
DOI 10.1172/jci125332
More from this paper
- LEAP2 acts as a GHSR antagonist that hyperpolarizes arcuate NPY neurons and prevents acyl-ghrelin from activating them, thereby blunting ghrelin's orexigenic effects.Strong
- Bariatric surgeries, specifically Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG), reduce fasting plasma LEAP2 levels in humans with obesity, correlating with weight loss and improved metabolic markers.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →